© 2026 Zoe. All rights reserved.
Zoe is a legal information platform. Always consult the Federal Register of Legislation for authoritative text.
[2023] NSWCATOD 14
NCAT Occupational
2022-08-19
Original judgment source is linked above.
agreed or assessed. (6) The non-disclosure order made on 18 March 2022 pursuant to s 64(1)(a) of the Civil and Administrative Tribunal Act (NSW) prohibiting the disclosure of the name of the patient, referred to as Patient A in these reasons, is continued and the non-disclosure order made on 19 August 2022 pursuant to s 64(1)(a) of the Civil and Administrative Tribunal Act (NSW) prohibiting the disclosure of the name of the patient, referred in the material before the Tribunal as Patient B, is continued. Catchwords: PROFESSIONS AND TRADES - health care professionals - medical practitioners - disciplinary action -prescribing drugs of addiction to drug addicted person - Professional Misconduct Legislation Cited: Civil and Administrative Tribunal Act 2013 (NSW) Health Practitioner Regulation (NSW) 2016 Health Practitioner Regulation National Law (NSW) Poisons and Therapeutic Goods Act 1966 (NSW) Poisons and Therapeutic Goods Regulation 2008 (NSW) Cases Cited: Briginshaw v Briginshaw (1983) 60 CLR 336 Gautaum v HCCC [2021] NSWCA 85 Health Care Complaints Commission v Do [2014] NSWCA 307 Health Care Complaints Commission v Sare [2018] NSWCATOD 190 Pillai v Messiter (1989) 16 NSWLR 197 Texts Cited: None cited Category: Principal judgment Parties: Health Care Complaints Commission (Applicant) Dr Geoffrey Samuel Au (Respondent) Representation: Counsel: E Bayley (Applicant) C Coventry (Respondent)
Solicitors: Health Care Complaints Commission (Applicant) Meriden Lawyers (Respondent) File Number(s): 2022/00061525 Publication restriction: Publication, broadcast or disclosure of the names or information identifying the patients referred to as "Patient A" or "Patient B" in the reasons or in the material before the Tribunal, is prohibited.
REASONS FOR DECISION
Complaint 1
Particular 1
1 (a): Failed to conduct a proper assessment before issuing prescriptions for fentanyl, oxycodone and alprazolam
1(d): The prescriptions for oxycodone, fentanyl and alprazolam were not issued for a therapeutic purpose
Particular 2
Particular 3
Particular 4
Particular 5:
5(a) Failure to obtain Patient A's medical history for the period since Patient A's last consultation with him on 28 December 2010
5(b) Failure to conduct a proper assessment before issuing prescriptions
5(e) the prescriptions were not issued for a proper therapeutic purpose
Particular 6
Particular 8
Particular 9
Complaint 2
Complaint 3
Discussion
Red flags 1. The practitioner continued to prescribe these drugs for the patient notwithstanding the existence of a number of "red flags" pointing to drug abuse that is the patient:
Doctor Shopper reports 1. The practitioner received three reports on 19 September 2017, May 2018 and July 2019, that the patient was attending other practitioners who were prescribing oxycodone, diazepam, amitriptyline hydrochloride and lithium for the patient. The reports reflect a three-month period up to the date of the report. 2. The first notification showed that the patient received 532 tablets of Oxycontin from the prescriptions of the practitioner and two other practitioners. The practitioner noted the contents of the report in his notes but did not attempt to contact the other prescribing practitioners. On 20 September 2017, the practitioner noted that he had spoken to the patient and noted the patient's agreement not to see other general practitioners and that he was be on a "3 month probation" and "denies diversion". The practitioner continued to prescribe to the patient. 3. On 22 May 2018, the practitioner received another report which indicated the patient attended one other practitioner and between them a total of 1036 oxycodone tablets were prescribed. The practitioner did not attempt to contact the other prescriber nor did he make a note of the report. He continued to prescribe to the patient. 4. On 23 July 2019, the practitioner received the third report which identified two other practitioners prescribing to the patient and in the reporting period, the patient received 720 oxycodone tablets. The practitioner made no note of the report and did not make inquiries of the other prescribers. 5. The practitioner continued to prescribe for the patient despite notes made by colleagues in the patient's file which raised concerns about the patient's use and potential abuse of the opioids.
Reported queries and concerns of dispensing pharmacists 1. The practitioner continued to prescribe notwithstanding being notified on 23 April 2018 by a pharmacist who asked whether he could dispense the drugs prescribed in a period shorter than that written on the prescription. The practitioner authorised the drugs to be dispensed. On 11 May 2018 the patient attended the practitioner who wrote PBS prescriptions for 56 tablets of 40mg oxycodone and 56 tablets of 80mg oxycodone and private prescriptions for 180 tablets of 1600mcg Actiq, 320 tablets of 8 mg Dilaudid and 200 tablets of 2mg Kalma 2. On 24 July 2019, a pharmacist contacted the practitioner and attached the forms necessary to obtain authorisation to prescribe Schedule 8 drugs. That afternoon the practitioner wrote private prescriptions for the patient for 40mg and 80mg oxycodone. The practitioner did not apply for authorisation. 3. On 26 July 2019, the practitioner noted the patient told him that a particular pharmacist would only give him a limited number of Kalma (alprazolam) tablets and he said that he would go to another pharmacy to have the drugs dispensed. That day the practitioner wrote PBS prescriptions for 28 tablets of both 40mg and 80mg oxycodone and also wrote private prescriptions for 150 tablets of 2mg Alprazolam. 4. After being contacted by a pharmacist on 31 July 2019 concerned about a prescription of 600 Actiq lozenges with no repeats, the practitioner authorised the pharmacy to dispense the drug at a rate of 3 boxes of 30 lozenges once per week. When the patient next returned on 21 August 2019, the practitioner prescribed, inter alia, 630 lozenges of Actiq. 5. On 29 October 2019 a pharmacist called the practitioner and told him that based on a conversation overheard between the patient and his daughter, the pharmacist was concerned that the patient was diverting the medication prescribed and suggested the practitioner write prescriptions for lesser amounts but with repeats. The patient attended the practitioner 4 days later and the practitioner wrote two PBS prescriptions for 40mg and 80mg oxycodone and one month later wrote PBS prescriptions with no repeats for 56 tablets each of 40mg and 80mg oxycodone and private prescriptions for 320 tablets of 8mg Dilaudid, 600 lozenges of Actiq and 150 tablets of 2mg alprazolam.
Record keeping
Risk of harm to the patient
Risk of harm to the community
Assessing the seriousness of the practitioner's conduct
The practitioner's submissions
Discussion
What order then should be made to protect the public
Orders 1. Pursuant to section 149C(l)(b) of the Health Practitioner Regulation National Law, the Tribunal suspends the respondent's registration for a period of 6 months from the date of this decision. 2. The Respondent's registration is subject to the following practice conditions: 1. To obtain Medical Council of NSW approval prior to changing the nature or place of his practice. 2. Not to possess, supply, administer or prescribe any 'drug of addiction' (Schedule 8 drug) as defined by the Poisons and Therapeutic Goods Act 1966 (NSW). 3. Not to possess, supply, administer or prescribe any Schedule 4 drug listed in Appendix D to the Poisons and Therapeutic Goods Regulation 2008 (NSW). 4. To practise under category B supervision in accordance with the Medical Council of NSW's Compliance Policy - Supervision (as varied from time time) and as subsequently determined by the appropriate review body. 1. At each supervision meeting the practitioner is to review and discuss his practice with his approved supervisor with particular focus on: 1. Problem Definition/Diagnosis 2. Management/Advice/Safety netting 3. Prescribing 4. Medical Records 1. To authorise the Medical Council of NSW to provide proposed and approved supervisors with a copy of the decision which imposed these conditions 1. Not to practise until a supervisor has been approved by the Medical Council of NSW. 2. To submit to an audit of his medical practice by a random selection of his medical records by a person or persons nominated by the Medical Council of NSW. 1. The Audit is to be held within 3 months from the date of decision and subsequently as required by the Council. 2. The auditor(s) is to assess his compliance with good medical record keeping standards and legislative requirements. 3. To authorise the auditor(s) to provide the Council with a report of their findings. 4. The practitioner is responsible for any costs arising out of compliance with the audit and any subsequent audits and reports. 1. To authorise and consent to any exchange of information between the Medical Council of NSW and Medicare Australia and Pharmaceutical Regulatory Unit for the purpose of monitoring compliance with these conditions. 1. The appropriate review body for the purpose of a review under section 163 - 163C of the Health Practitioner Regulation National Law is the Medical Council of NSW when the respondent has a principal place of practice in NSW. 2. Sections 125 and 127 of the Health Practitioner Regulation National Law are to apply while the respondent's principal place of practice is anywhere in Australia other than NSW, so that a review of these conditions can be conducted by the Medical Board of Australia 3. The respondent is to pay the costs of the applicant, the Health Care Complaints Commission, as agreed or assessed. 4. The non-disclosure order made on 18 March 2022 pursuant to s 64(1)(a) of the Civil and Administrative Tribunal Act (NSW) prohibiting the disclosure of the name of the patient, referred to as Patient A in these reasons, is continued and the non-disclosure order made on 19 August 2022 pursuant to s 64(1)(a) of the Civil and Administrative Tribunal Act (NSW) prohibiting the disclosure of the name of the patient, referred in the material before the Tribunal as Patient B, is continued.
I hereby certify that this is a true and accurate record of the reasons for decision of the New South Wales Civil and Administrative Tribunal. Registrar I hereby certify that this is a true and accurate record of the reasons for decision of the Civil and Administrative Tribunal of New South Wales. Registrar
Amendments 22 February 2023 - Coversheet - Name of Respondent corrected. DISCLAIMER - Every effort has been made to comply with suppression orders or statutory provisions prohibiting publication that may apply to this judgment or decision. The onus remains on any person using material in the judgment or decision to ensure that the intended use of that material does not breach any such order or provision. Further enquiries may be directed to the Registry of the Court or Tribunal in which it was generated. Decision last updated: 22 February 2023
Health Care Complaints Commission
Dr Geoffrey Samuel AU